Intrinsiqq
Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc. Financials

MIST

⊜ Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 9 available years
Income Statement
TTM
DEC 2025
2:1 split
DEC 2024
~1.6:1 split
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue$1–––––
Cost of Revenue$0–––––
Gross Profit$1–––––
General & Administrative$42$17$17$16$16$12
Research & Development$15$18$14$31$40$39
Total Operating Expenses$83–––––
Operating Income-$82-$62-$42-$61-$60-$43
Non-Operating
Net Interest Expense-$6-$1$1$1––
Other Non-Operating Income (Expense)–$0$0$0––
EBT (Earnings Before Tax)–-$63-$42-$60-$58-$43
Net Income
Net Income-$88-$63-$42-$60-$58-$43
Per Share Data
Revenue Per Share$0.01–––––
EPS (Basic)-$0.92-$0.75-$0.67-$1.39-$1.38-$1.02
EPS (Diluted)-$0.92-$0.75-$0.67-$1.39-$1.38-$1.02
Shares Outstanding124.5M106.2M53.4M33.5M34.3M29.9M

Milestone Pharmaceuticals (MIST) financials: revenue, profit and margins

Milestone Pharmaceuticals (MIST) generated about n/a in revenue and -$84 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Milestone Pharmaceuticals profitable?+

Milestone Pharmaceuticals reported about -$84 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 12 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 14 Oct 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with MIST

CompareIntrinsic value
BSPKBespoke Extracts Inc.
$0.00+0.00%30
LEXXLexaria Bioscience Corp.
$4.07+0.99%10
GANXGain Therapeutics Inc.
$1.11-3.48%25
PTGXProtagonist Therapeutics Inc.
$143.37+2.23%54
XENEXenon Pharmaceuticals Inc.
$39.19+2.50%10
ONCBeOne Medicines Ltd.
$377.78+6.42%65
ASMBAssembly Biosciences Inc.
$19.87-0.25%19
VRTXVertex Pharmaceuticals Incorporated
$549.04+3.44%47

Held by ETFs

MIST is in 2 US ETFs. The largest of them, with MIST's weight in each:

Spot a number that looks wrong? Check it in MIST's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing MIST

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.